Precirix
Precirix is a clinical-stage Brussels-based biopharmaceutical company developing precision radiopharmaceuticals that use camelid single-domain antibodies labeled with radiometals to treat HER2-positive and FAP-expressing solid tumors, with CAM-H2 in Phase I/II and CAM-FAP-Ac-225 IND-approved.
- Company typePrivate
- Founded2014
- HeadquartersBrussels, Belgium
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Precirix does
Precirix is a privately-held clinical-stage biopharmaceutical company headquartered in Brussels, Belgium, founded in 2014 as a Vrije Universiteit Brussel (VUB) spin-off (originally named Camel-IDS, rebranded in September 2020). The company designs and develops precision radiopharmaceuticals for cancer treatment using a proprietary platform built on camelid single-domain antibodies (sdAbs) labeled with therapeutic and diagnostic radiometals. Its lead asset CAM-H2 is an sdAb targeting HER2, labeled with Iodine-131, currently in a Phase I/II study (NCT04467515) for HER2-positive metastatic breast and gastric cancer, including brain metastases where limited options exist. The pipeline has expanded to include CAM-FAP-Ac-225 (targeted alpha therapy against fibroblast activation protein, FDA IND accepted July 2025), CAM-FAP-Ga-68 (companion diagnostic imaging agent), CAM-HER2-Pb-212 (Lead-212 alpha therapy via partnership with Orchestra Life Sciences), and CAM-FR (folate receptor alpha, preclinical for ovarian cancer).
The sdAb platform is designed to combine the high target specificity of monoclonal antibodies with the fast tumor penetration and rapid blood clearance of peptides, enabling targeted radionuclide therapy with long tumor retention times while sparing healthy tissue. The platform is multi-isotope (I-131, Ac-225, Pb-212, Ga-68) and theranostic-capable, allowing the same molecule to be used for patient imaging and treatment selection followed by therapeutic dosing. Precirix is pre-revenue and its stated revenue model is one-time licensing or future product sales following regulatory approval; the company currently monetizes its research through scientific publishing, conference presentations, and an Academic Access Program for CAM-FAP-Ga-68, while clinical manufacturing is outsourced to CDMOs (3P Biopharmaceuticals, Evergreen Theragnostics, IFE) and isotope supply is secured via Eckert & Ziegler and Orchestra Life Sciences partnerships. CAM-H2 is explicitly available for partnering or out-licensing, and the company has signaled openness to strategic transactions for the platform or programs.
Precirix firmographics
Firmographics- Name
- Precirix
- Legal name
- Precirix NV
- Website
- https://precirix.com
- Company type
- Private
- Founded year
- 2014
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Precirix is a clinical-stage Brussels-based biopharmaceutical company developing precision radiopharmaceuticals that use camelid single-domain antibodies labeled with radiometals to treat HER2-positive and FAP-expressing solid tumors, with CAM-H2 in Phase I/II and CAM-FAP-Ac-225 IND-approved.
- Ownership category
- akta.pro rank
Precirix industry classification
Industry- Product category
- Precision Radiopharmaceuticals / Targeted Radionuclide Therapy
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- SIC
- Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB)
- akta.pro secondary industries
- Monoclonal Antibody Therapeutics (mAbs) (HLAAAAAA), Antibody-Drug Conjugates (ADCs) & Antibody Conjugates (HLAAAAAE)
Keywords
Where Precirix is headquartered
LocationHeadquarters
- HQ city
- Brussels
- HQ country
- Belgium
- HQ region
- Europe
Offices1 record
Markets served
Precirix business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- Radiopharmaceutical Development: Pre-revenue clinical stage company developing precision radiopharmaceuticals for cancer treatment. Revenue will be generated through product sales upon regulatory approval.
Go-to-market motion1 record
Distribution channels3 records
Marketing channels4 records
Precirix product offering
Product offeringCore offering
Precirix develops precision radiopharmaceuticals that combine camelid single-domain antibodies (sdAbs) with therapeutic and diagnostic radioisotopes to selectively target cancer cells. Its lead candidates include CAM-H2 (HER2-targeting, Iodine-131, in Phase I/II), CAM-FAP-Ac-225 (FAP-targeting alpha therapy, FDA IND accepted July 2025), CAM-FAP-Ga-68 diagnostic imaging agent, CAM-HER2-Pb-212, and CAM-FR. The company generates value primarily through out-licensing and partnering of its assets rather than direct commercialization.
Product overview
Precirix is a clinical-stage biopharmaceutical company developing precision radiopharmaceuticals using camelid single-domain antibodies (sdAbs) labeled with radiometals. The company's portfolio consists of its proprietary CAM-TRT Platform enabling development of sdAb-based radiopharmaceuticals, with lead products including CAM-H2 (HER2-targeting with Iodine-131, in Phase I/II), CAM-FAP-Ac-225 (FAP-targeting with Actinium-225, IND approved July 2025 for Phase 1), CAM-FAP-Ga-68 (diagnostic imaging agent), CAM-HER2-Pb-212 (Lead-212 therapeutic with Orchestra Life Sciences), and CAM-FR (folate receptor targeting for ovarian cancer in preclinical stage). The platform enables both therapeutic and diagnostic (theranostic) applications.
Differentiator
Problem solved
Functional benefit
Products and services
- CAM-H2 HER2-targeting camelid single-domain antibody (sdAb) radiolabeled with Iodine-131, designed to effectively irradiate HER2-positive metastatic cancers including brain metastases while sparing healthy tissue. Currently in Phase I/II clinical trial. Available for partnering or out-licensing.
- CAM-FAP-Ac-225 Single-domain antibody construct targeting Fibroblast Activation Protein alpha (FAP) labeled with Actinium-225 for targeted alpha therapy of FAP-expressing solid tumors. Lead clinical program; potential first-in-class alpha-emitting targeted radiotherapy against the pan-tumor target FAP.
- CAM-FAP-Ga-68 Gallium-68 labeled imaging agent for PET imaging of FAP-expressing solid tumors. Offered to academic researchers through the CAM-FAP Academic Access Program for investigator-initiated imaging studies.
- CAM-HER2-Pb-212
Quantifiable outcome
- Phase I study completed demonstrating safety and specific targeting of cancer cells
- +2 more outcomes
Companies that use Precirix
Customer profileSegments3 records
Ideal customer profiles3 records
Precirix technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Precirix partnerships and signals
Strategic signalPartnerships
Seven partnerships are on record, tiered core and strategic.
- Vrije Universiteit Brussel (VUB)coreResearch collaboration on radio-fluorination for sdAbs and immune modulation studies. VUB is the academic institution where Precirix originated as a spin-off in 2014.
- Orchestra Life SciencesstrategicStrategic partnership for access to Lead-212 (Pb-212) radioisotope through Orchestra's TAG1 generator for targeted alpha therapy development.
- Eckert & Ziegler EurotopecoreCollaboration for development of automated production process for 68Ga-based diagnostic compounds using Eckert & Ziegler's synthesis equipment.
- Eckert & ZieglercoreAgreement for priority supply of Actinium-225 radioisotope for clinical trials. German company specializing in isotope-related components for nuclear medicine.
- IFE (Institute for Energy Technology)coreClinical trial manufacturing agreement for supply of radiopharmaceuticals in Europe. Norwegian manufacturer of radiopharmaceutical products.
- 3P BiopharmaceuticalscoreAlliance for clinical manufacturing of single domain antibodies. CDMO based in Spain specializing in process development and GMP manufacturing of biological products.
- Evergreen TheragnosticscoreManufacturing partnership for CAM-H2 production at Evergreen's state-of-the-art GMP facility in Springfield, New Jersey. Supports North American clinical trial supply.
Scale indicators6 records
Recent moves7 records
Expansion highlights6 records
Precirix competitors and assessment
Company assessmentDirect peers
- Telix Pharmaceuticals: Australian commercial-stage radiopharma company developing HER2-targeted imaging (TLX591) and a broader pipeline of targeted radiopharmaceuticals. Most directly comparable to Precirix given overlapping HER2 radiopharma programs and parallel therapeutic-plus-diagnostic strategies.
- POINT Biopharma: Radioligand therapy company developing PNT2002 (PSMA-Lu-177) and PNT2003 plus actinium-based alpha programs. Acquired by Eli Lilly for $1.4B in 2023. Closely comparable clinical-stage radiopharma with parallel alpha/beta emitter strategy.
- Fusion Pharmaceuticals: Canadian targeted alpha therapy company developing Ac-225-based radiopharmaceuticals across multiple targets. Acquired by AstraZeneca for $2.4B in 2024. Highly comparable as clinical-stage alpha-emitter specialist.
- RayzeBio: US radiopharmaceutical company developing actinium-225-based targeted radiotherapies for solid tumors. Acquired by Bristol Myers Squibb for $4.1B in 2024. Direct peer given parallel alpha-emitter therapeutic focus.
- ITM Isotope Technologies Munich: German radiopharmaceutical company developing targeted radionuclide therapies (Lu-177 and Ac-225 based) with own isotope production capabilities. Comparable clinical-stage radioligand therapy developer with European footprint.
- Actinium Pharmaceuticals: US clinical-stage company developing alpha-emitting radiotherapies (Ac-225, I-131) for hematologic and solid tumors. Direct peer with similar early-clinical-stage profile and alpha-emitter focus.
- Ariceum Therapeutics: Berlin-based clinical-stage radiopharma company developing sdAb-based radiopharmaceuticals for solid tumors. Highly comparable to Precirix given parallel use of single-domain antibody scaffolds and targeted radionuclide therapy approach.
Broad incumbents
- Novartis (Advanced Accelerator Applications): Owner of Lutathera (Lu-177) and Pluvicto (Lu-177 PSMA-617), the dominant approved radioligand therapy franchise. Broad incumbent setting competitive benchmarks for all clinical-stage radiopharma developers including Precirix.
- Bayer (Pharmaceuticals): Acquired Algeta ASA for $2.9B in 2014, gaining Xofigo (Ra-223) and alpha-emitter expertise. Major incumbent in radiopharmaceuticals with established commercial and manufacturing infrastructure.
- Lantheus Holdings: US radiopharmaceutical company with approved products (Definity, Xenon-133) and pipeline including PSMA-targeted and other radioligand therapies. Broad incumbent serving as M&A consolidator in the radiopharma space.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks7 records
Key highlights7 records
Customer concentration
Precirix social profiles
Digital presencePrecirix financial estimates
Financial estimateRevenue estimate
Valuation estimate
Precirix leadership team
Management profileNumber of profiles
Profiles13 records
Precirix funding detail
Funding detailFunding overview
Funding rounds2 records
Investors9 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Precirix M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Precirix
What does Precirix do?
Precirix develops precision radiopharmaceuticals that combine camelid single-domain antibodies (sdAbs) with therapeutic and diagnostic radioisotopes to selectively target cancer cells. Its lead candidates include CAM-H2 (HER2-targeting, Iodine-131, in Phase I/II), CAM-FAP-Ac-225 (FAP-targeting alpha therapy, FDA IND accepted July 2025), CAM-FAP-Ga-68 diagnostic imaging agent, CAM-HER2-Pb-212, and CAM-FR. The company generates value primarily through out-licensing and partnering of its assets rather than direct commercialization.
Is Precirix a public or private company?
Precirix is a private company. It is classified as venture growth investor backed and is currently operating.
When was Precirix founded?
Precirix was founded in 2014. It employs 11 to 50 people.
Where is Precirix based?
Precirix is headquartered in Brussels, Belgium, in the Europe region.
How does Precirix make money?
One revenue line is on record: radiopharmaceutical Development.
Who are Precirix's main competitors?
Direct peers on record are Telix Pharmaceuticals, POINT Biopharma, Fusion Pharmaceuticals, RayzeBio, ITM Isotope Technologies Munich, Actinium Pharmaceuticals and Ariceum Therapeutics. Broad incumbents are Novartis (Advanced Accelerator Applications), Bayer (Pharmaceuticals) and Lantheus Holdings.
Does Precirix have an API?
No public API is recorded for Precirix.
What industry is Precirix in?
Precirix's product category is Precision Radiopharmaceuticals / Targeted Radionuclide Therapy. Its primary akta.pro industry code is HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering), with a secondary code of HLAAAAAA, Monoclonal Antibody Therapeutics (mAbs). Its NAICS code is 541714 and its SIC code is 2834.